Publications by authors named "Pawel Robak"

Claim this Profile
M
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.
María-Victoria Mateos, Suzanne Trudel, Hang Quach, Paweł Robak, Meral Beksac

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.
Meletios A Dimopoulos, Meral Beksac, Ludek Pour, Sosana Delimpasi, Vladimir Vorobyev, Paweł Robak

Lancet Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs.
Tadeusz Robak, Elżbieta Iskierka-Jażdżewska, Anna Puła, Pawel Robak, Bartosz Puła

J Clin Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.
Luca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, Mark van Duin, Evangelos Terpos, Pawel Robak

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burkitt lymphoma in patients with chronic lymphocytic leukemia and other indolent B-cell lymphoid malignancies.
Tadeusz Robak, Agnieszka Pluta, Pawel Robak, Agnieszka Janus, Ewa Wawrzyniak

Leuk Lymphoma· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Vania Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCL-2 and BTK inhibitors for chronic lymphocytic leukemia: current treatments and overcoming resistance.
Tadeusz Robak, Magdalena Witkowska, Anna Wolska-Washer, Paweł Robak

Expert Rev Hematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of antibody therapies in treating relapsed chronic lymphocytic leukemia: a review.
Magdalena Witkowska, Agata Majchrzak, Paweł Robak, Anna Wolska-Washer, Tadeusz Robak

Expert Opin Biol Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors and Profile of Severe Infectious Complications in Multiple Myeloma Patients Treated with Daratumumab-Based Regimens: A Machine Learning Model for Pneumonia Risk.
Damian Mikulski, Marcin Kamil Kędzior, Grzegorz Mirocha, Katarzyna Jerzmanowska-Piechota, Żaneta Witas, Paweł Robak, Tadeusz Robak

Cancers (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Thierry Facon, Meletios-Athanasios Dimopoulos, Xavier P Leleu, Meral Beksac, Ludek Pour, Pawel Robak

N Engl J Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.
Sosana Delimpasi, Meletios A Dimopoulos, Jan Straub, Argiris Symeonidis, Luděk Pour, Pawel J Robak

Am J Hematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment with cladribine in a patient with Rosai-Dorfman disease complicated by severe, prolonged marrow aplasia.
Tadeusz Robak, Marcin Braun, Anna Guminska, Elżbieta Iskierka-Jażdżewska, Paweł Robak

Leuk Lymphoma· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.
Tadeusz Kubicki, Dominik Dytfeld, David Barnidge, Dhananjay Sakrikar, Anna Przybyłowicz-Chalecka, Paweł Robak, Tadeusz Robak

Blood· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Vania Hungria, Pawel Robak, Marek Hus, Vera Zherebtsova, Christopher Ward

N Engl J Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
Meletios Athanasios Dimopoulos, Meral Beksac, Ludek Pour, Sosana Delimpasi, Vladimir Vorobyev, Pawel Robak

N Engl J Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.
Fredrik H Schjesvold, Heinz Ludwig, Sossana Delimpasi, Pawel Robak, Daniel Coriu

Haematologica· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.
Tadeusz Kubicki, Krzysztof Jamroziak, Paweł Robak, Jarosław Czyż, Agata Tyczyńska, Tadeusz Robak

Pol Arch Intern Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Anna Wolska-Washer, Paweł Robak, Magdalena Witkowska, Tadeusz Robak

Expert Opin Drug Metab Toxicol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens - pilot study.
Anna Puła, Tadeusz Robak, Izabela Dróżdż, Konrad Stawiski, Aleksander Rycerz, Paweł Robak

Leuk Lymphoma· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
Tadeusz Kubicki, Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, Paweł Robak

Br J Haematol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An elevated systemic inflammation index is related to an inferior response to pomalidomide and dexamethasone treatment in patients with relapsed and refractory multiple myeloma.
Damian Mikulski, Paweł Robak, Grzegorz Mirocha, Wiktoria Ryżewska, Kamila Stańczak, Tadeusz Robak

Contemp Oncol (Pozn)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies.
Paweł Robak, Magda Witkowska, Anna Wolska-Washer, Tadeusz Robak

Expert Opin Drug Discov· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.
Irit Avivi, David H Vesole, Julio Davila-Valls, Lidia Usnarska-Zubkiewicz, Magdalena Olszewska-Szopa, Paweł Robak

Cancers (Basel)· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia.
Magdalena Witkowska, Agata Majchrzak, Paweł Robak, Anna Wolska-Washer, Tadeusz Robak

Expert Opin Drug Metab Toxicol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atypical Chronic Lymphocytic Leukemia-The Current Status.
Tadeusz Robak, Anna Krawczyńska, Barbara Cebula-Obrzut, Marta Urbaniak, Elżbieta Iskierka-Jażdżewska, Paweł Robak

Cancers (Basel)· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis